Table 1.
Characteristics of Type 2 MI Patients Stratified by Median Home‐Time at 1 Year (N=289)
| Home‐Time Below Mediana (n=144) | Home‐Time Equal to or Above the Mediana (n=145) | |
|---|---|---|
| Demographics | ||
| Age, mean (SD) | 75.8 (13.4) | 72.0 (13.2) |
| Men | 81 (56.2%) | 84 (57.9%) |
| Race | ||
| White | 126 (87.5%) | 115 (79.3%) |
| Black | 13 (9.0%) | 17 (11.7%) |
| Other | 5 (3.5%) | 13 (9.0%) |
| Past medical history | ||
| Diabetes mellitus | 68 (47.2%) | 56 (38.6%) |
| Smoker | 16 (11.1%) | 17 (11.7%) |
| COPD | 35 (24.3%) | 26 (17.9%) |
| Hypertension | 114 (79.2%) | 119 (82.1%) |
| Hyperlipidemia | 88 (61.1%) | 92 (63.4%) |
| Previous MI | 35 (24.3%) | 29 (20%) |
| Previous PCI | 29 (20.1%) | 22 (15.2%) |
| Previous CABG | 21 (14.6%) | 26 (17.9%) |
| Heart failure | 87 (60.4%) | 62 (42.8%) |
| Known CAD | 74 (51.4%) | 77 (53.1%) |
| Atrial fibrillation | 55 (38.2%) | 36 (24.8%) |
| Previous stroke or TIA | 27 (18.8%) | 30 (20.7%) |
| PAD | 39 (27.1%) | 28 (19.3%) |
| Cancer history | 33 (22.9%) | 26 (17.9%) |
| CKD | 79 (54.9%) | 60 (41.4%) |
| Dialysis | 19 (13.2%) | 14 (9.7%) |
| Liver cirrhosis | 7 (4.9%) | 4 (2.8%) |
| Prior GI bleed | 13 (9.0%) | 12 (8.3%) |
| Diagnostic work‐up | ||
| Ejection fraction (N=99), mean % (SD) | 53.1% (17.4) | 54.1% (15.7) |
| Positive stress test/number performed (%) | 4/13 (30.8%) | 6/18 (33.3%) |
| Coronary angiography with obstructive disease/number performed (%) | 6/12 (50%) | 13/28 (46.4%) |
| HbA1c level (N=189) (SD) | 6.4% (2.1) | 6.5% (2.2) |
| LDL‐C level (N=212), mean mg/dL (SD) | 61.9 (21) | 81.8 (47.5) |
| Initial conventional troponin concentration (N=86), mean ng/mL (SD) | 0.17 (0.2) | 0.15 (0.2) |
| Peak conventional troponin concentration (N=86), mean ng/mL (SD) | 0.41 (0.7) | 0.40 (0.2) |
| Initial hs troponin concentration (N=203), mean ng/L (SD) | 128.1 (253.2) | 58.1 (64.1) |
| Peak hs troponin concentration (N=203), mean ng/L (SD) | 282.2 (579.9) | 150.6 (304.4) |
| GRACE score | ||
| 1–109 | 21 (14.6%) | 28 (19.3%) |
| 110–140 | 33 (22.9%) | 61 (42.1%) |
| >140 | 90 (62.5%) | 55 (37.9%) |
| TIMI score | ||
| 1 | 12 (8.3%) | 9 (6.2%) |
| 2 | 18 (12.5%) | 30 (20.7) |
| 3 | 31 (21.5%) | 29 (20%) |
| 4 | 36 (25%) | 33 (22.8%) |
| 5 | 32 (22.2%) | 34 (23.4%) |
| 6 | 12 (8.3%) | 7 (4.8%) |
| 7 | 3 (2.1%) | 3 (2.1%) |
| In‐hospital treatment | ||
| Aspirin | 109 (75.7%) | 123 (84.8%) |
| Clopidogrel | 20 (13.9%) | 14 (9.7%) |
| β‐blocker | 103 (72%) | 98 (69.5%) |
| ACEi/ARB | 36 (25%) | 46 (31.7%) |
| Statin | 119 (82.6%) | 112 (77.2%) |
| PCI | 2 (1.4%) | 3 (2.1%) |
| CABG | 2 (1.4%) | 1 (0.7%) |
| Discharge medications | ||
| Aspirin | 107 (74.3%) | 120 (82.8%) |
| Clopidogrel | 18 (12.5%) | 18 (12.4%) |
| Ticagrelor | 1 (0.7%) | 1 (0.7%) |
| ACEi/ARB | 41 (28.5%) | 56 (38.6%) |
| Statin | 119 (82.6%) | 111 (76.6%) |
| β‐blocker | 104 (72.2%) | 109 (75.2%) |
ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; GRACE, Global Registry of Acute Coronary Events; hs, high sensitivity, LDL‐C, low‐density lipoprotein‐cholesterol; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; and TIMI, Thrombolysis in Myocardial Infarction.
a
Median home‐time 347 (interquartile range, 203–362) days.